The Quebec Immunization Committee (CIQ) has just issued its opinion on Covifenz, the vaccine against COVID-19 produced by Medicago. It recommends its use for people aged 18 to 64 who have a contraindication to the administration of a messenger RNA vaccine or who would refuse the latter type of vaccine.
The CIQ continues to favor messenger RNA vaccines, such as those from Pfizer and Moderna, since “their effectiveness appears to be slightly higher” than recombinant protein vaccines against COVID-19 such as Nuvaxovid, from Novavax, and Covifenz, from Medicago. .
The committee specifies, however, in its opinions concerning Nuvaxovid and Covifenz, that these vaccines are based “on a classic technology, which could promote the acceptability of a vaccination for people who have a real fear of vaccines based on more recent technologies. like messenger RNA.
According to the Ministry of Health and Social Services (MSSS), doses of Covifenz could be delivered to Quebec “around the end of May”.
A week ago, the Quebec government announced that 7,500 doses of the Novavax vaccine had been distributed in establishments in the health network. Since then, very few non-vaccinated Quebecers have gone to a vaccination center to get it. According to the MSSS, 293 doses have been administered so far, including 244 first doses.
To see in video